Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0699790 (
colon cancer
)
28,837
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A novel member of the human AMPK family,
ARK5
, was recently discovered to be a key molecule in mediating cancer cell migration activity in human pancreas cancer cell line PANC-1, and its activation was found to be induced by Akt-dependent phosphorylation at Ser 600. DNA array analysis with 241 paired cDNAs from 13 different types of tumors and corresponding normal tissues derived from cancer patients revealed
ARK5
overexpression in the samples of colorectal cancer.
ARK5
expression was measured and an in vitro invasion assay was performed in six human colorectal cancer cell lines, WiDr, HCT-15, DLD-1, SW620, LoVo, and SW480, and since high invasion activity was concordant with higher
ARK5
expression,
ARK5
expression was examined in relation to tumor progression and metastatic activity in clinical samples. In 56 clinical samples of primary colorectal cancers and their liver metastases, higher
ARK5
expression was observed in the samples from more advanced cases, and much higher expression was observed in the liver metastases. In situ hybridization analysis showed
ARK5
overexpression in tumor cells. Based on these findings, we propose that
ARK5
overexpression is involved in tumor progression of
colon cancer
clinically.
...
PMID:ARK5 expression in colorectal cancer and its implications for tumor progression. 1498 52
ARK5
, AMP-activated protein kinase (AMPK)-related protein kinase mediating Akt signals, is closely involved in tumor progression, and its stage-associated expression was observed in colorectal cancer. In this study, we found
ARK5
expression in multiple myeloma cell lines expressing c-MAF and MAFB. In addition, gene expression profiling of 351 clinical specimens revealed
ARK5
expression in primary myelomas expressing c-MAF and MAFB, suggesting that
ARK5
may be a transcriptional target of the Large-MAF family. Sequence analysis of the
ARK5
gene promoter revealed that it contains two putative MAF-recognition element (MARE) sequences. In support of this hypothesis,
ARK5
was induced when an MAFB or c-MAF expression vector was introduced into non-
ARK5
-expressing
colon cancer
cells. Furthermore,
ARK5
promoter activity was dramatically decreased by mutation or deletion of MARE sequences. Chromatin immunoprecipitation assays revealed an interaction between the Large-MAF family proteins and MARE sequences in the
ARK5
promoter. Moreover, in
ARK5
mRNA-expressing multiple myeloma lines, but not in
ARK5
-negative lines, insulin-like growth factor (IGF)-1 increased invasion activity. IGF-1-induced invasion was reproduced when
ARK5
was overexpressed in Burkitt's lymphoma and plasmacytoma lines. Based on results, we conclude that
ARK5
is a transcriptional target of the Large-MAF family through MARE sequence and that
ARK5
may in part mediate the aggressive phenotype associated with c-MAF- and MAFB-expressing myelomas.
...
PMID:ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma. 1604 63